ThromboGenics and BioInvent Awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme
The financial support from EU's Framework Programme 6 will contribute over the next two years to the further development of the antibody-based product candidate TB-403 for treatment of tumours, inflammation and eye disease. TB-403 has shown good inhibition of PlGF-associated angiogenesis and tumour growth in preclinical models. The first stages in the toxicology programme for this product candidate have already started. The PlGF growth factor is secreted by tumours and is specifically expressed in cancer and chronic inflammatory conditions. It affects the formation of new blood vessels in tissue that are under stress. PlGF does not seem to affect normal, physiological angiogenesis, unlike other treatments already on the market. Therefore, the inhibition of PlGF is expected to have fewer side effects than existing anti-VEGF agents, but will still have the desired effect on various diseases.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.